Injectable peptide drugs have transformed treatment for type 2 diabetes, obesity, cardiovascular disease, and inflammatory conditions, yet their route of administration imposes a daily or weekly burden that erodes patient adherence in chronic disease settings. The gastrointestinal tract is, in practice, a highly efficient peptide-destruction system. A 2026 review of strategies for overcoming oral peptide barriers identifies four principal obstacles: a harsh pH environment, enzymatic degradation, a thick mucus layer, and the intestinal epithelial barrier, any combination of which can reduce systemic exposure to near-zero.
Most oral peptide candidates achieve bioavailability below one percent. The few that reach approval require strict fasting conditions, introducing a separate adherence problem. Cyprumed GmbH announced that MSD has initiated a Phase 1 clinical trial of one of its proprietary drug candidates formulated using Cyprumed's licensed oral delivery technology, marking the first time the platform has entered human clinical development.
Why does food undermine oral peptide absorption?
Food-effect variability is the central reason oral peptide absorption fails to translate reliably from fasted pharmacokinetic studies to real-world use. A 2026 pharmacokinetic analysis shows that absorption enhancers are acutely sensitive to dietary components. Oral semaglutide, the most clinically advanced approved oral peptide, must be taken on an empty stomach with no more than four ounces of water, followed by a 30-minute post-dose fast; even under those controlled conditions, coefficients of variation for oral peptide absorption frequently exceed 50 to 60 percent.
For people with chronic diseases receiving peptide-based glucagon-like peptide-1 (GLP-1) therapies, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, or immunomodulatory macrocycles, meal-timing restrictions create compounding adherence burdens that can undermine otherwise effective treatments. Florian Föger, CEO of Cyprumed, said the platform's ambition extends beyond enabling absorption: "Our goal is not only to enable oral delivery of peptides, but also to overcome key challenges associated with oral administration, including the impact of food on drug absorption. This could give patients greater flexibility in when and what they eat, while potentially providing more consistent drug exposure."
How Cyprumed's tablet technology works
Cyprumed's platform is a tablet-based delivery system for therapeutic peptides built entirely around already-approved pharmaceutical excipients. Rather than developing novel permeation agents, a process that can require decades of toxicological characterization, the formulation combines established permeation enhancers with redox-active co-excipients. Published work in the oral peptide delivery literature shows that trace-metal and reducing-agent co-excipients can increase intestinal absorption relative to a permeation enhancer alone through redox-mediated modulation of protease activity, an approach Cyprumed's scientific founder documented in preclinical models.
Martin Werle, COO of Cyprumed, emphasized the dual objective of bioavailability and scale: "Our tablet technology is designed to combine strong oral bioavailability for peptides with a practical and scalable formulation approach. The platform relies on well-characterized pharmaceutical excipients, providing a strong foundation from both a safety and regulatory perspective, while also supporting robust manufacturability and scalability."
The following platform attributes span peptide class coverage, regulatory positioning, and commercial readiness, according to the company:
- Peptide class coverage: Compatible with GLP-1 analogues, macrocyclic peptides, and mini-proteins
- Regulatory foundation: Built on approved pharmaceutical excipients, avoiding the novel excipient approval burden
- Pharmacokinetic goal: Designed to reduce food-effect variability and deliver more consistent systemic exposure
- Manufacturability: Scalable formulation approach based on established pharmaceutical processing
- Commercial model: Non-exclusive licensing structure enabling multi-partner, multi-target deployment
MSD collaboration: $493 million structure, undisclosed target
Under a Non-Exclusive License and Option Agreement announced in April 2025, MSD gained non-exclusive global rights to Cyprumed's oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license the technology for individual targets. Cyprumed is eligible for up to $493 million in upfront, development, regulatory, and net sales milestones, with additional payments if MSD exercises the exclusive license option. MSD controls all research and development, manufacturing, and commercialization; the specific peptide target now entering Phase 1 has not been disclosed.
MSD has developed a focused portfolio in oral macrocyclic peptide science, with candidates across cardiovascular and other therapeutic areas designed to combine the target selectivity of biologics with the convenience of a daily pill. Its track record of advancing oral macrocyclic candidates from discovery through regulatory approval makes the Cyprumed collaboration a fit for programs where formulation is a rate-limiting step. Cyprumed has also disclosed partnerships with Bayer, Boehringer Ingelheim, and Ferring, indicating the platform is under evaluation across multiple pharmaceutical development contexts.
Four oral peptide formulation approaches compared
Recent Regulatory approvals confirmed that the oral peptide absorption problem is solvable; each approval also demonstrated that solutions remain narrowly tailored to specific molecules and formulation approaches. The 2019 approval of the first oral GLP-1 analogue for type 2 diabetes validated sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC)-based gastric absorption but requires strict fasting and produces highly variable systemic exposure. Two subsequent approvals in 2026 extended oral peptide precedent to the IL-23 receptor and PCSK9 target classes using distinct structural and formulation strategies, yet the food-effect challenge remains unaddressed in any currently marketed oral peptide.
Formulation Approach | Technology Basis | Regulatory Excipient Status | Food-Effect Management |
|---|---|---|---|
Cyprumed oral peptide platform | Tablet with approved excipient-based enhancement and redox-active co-excipients | Approved excipients throughout | Specifically targeted by design; clinical data pending |
SNAC-based gastric absorption | Local pH buffering; pepsin protection; transcellular transport enhancement | SNAC approved for marketed oral peptide | Strict fasting required; food markedly reduces exposure |
C10 intestinal absorption enhancement | Tight junction modulation; membrane fluidization; paracellular transport | C10 is an established excipient | Variable; demonstrated clinical viability with once-daily dosing |
Lipid-based formulation with enteric protection | Encapsulation in lipid vehicles with enteric-coated capsule dissolution | Established lipid excipients and enteric polymers | Under active investigation; gastric fluid dilution a persistent challenge |
Oral peptide delivery: food-effect variability remains the defining challenge
Cyprumed's Phase 1 trial with MSD is the first human study of an oral peptide platform built specifically to reduce fed-state absorption variability, a limitation that persists across every currently approved oral peptide formulation. Phase 1 programs for oral peptide formulations typically assess pharmacokinetics, safety, and tolerability across fed and fasted states, making exposure variability under fed conditions the critical readout for this technology. Clinical translation of Cyprumed's preclinical profile will determine the pace of program advancement and the scope of milestones it can unlock across the MSD collaboration and Cyprumed's broader multi-partner pipeline.
This article is based on a press release issued by Cyprumed GmbH and was produced under Drug Discovery News' AI Editorial Guidelines.
